The QualityStocks Daily Tuesday, April 2nd, 2019

Today's Top 3 Investment Newsletters

Schaeffer's (AVEO) +42.34%

StockMarketWatch (EDAP) +42.14%

QualityStocks (MOLOF) +31.18%

The QualityStocks Daily Stock List

Flower One Holdings, Inc. (FLOOF)

Trading View, InvestorsHub, The Street, Street Insider, New Cannabis Ventures, Investing News, GlobeNewswire, Morningstar, GuruFocus, The Cannabis Investor, Barchart, Seeking Alpha, Nasdaq, Dividend Investor, and Otc.watch reported on Flower One Holdings, Inc. (FLOOF), and today are highlighting the Company, here at the QualityStocks Daily Newsletter.

Flower One Holdings, Inc. is the owner of Nevada's largest cannabis cultivation and production facility. The Company works to leverage the industry's top agricultural technologies, using unique growing and sustainability practices to cultivate high-quality cannabis at scale for Nevada's increasing cannabis market. Flower One Holdings is based in Toronto, Ontario and the Company lists on the OTC Markets’ OTCQB.

Flower One’s mission is to build a recognizable international brand. It aims to do so while maintaining an agile approach to customized orders of cannabis flower and cannabis derivatives. The Company has the largest commercial scale greenhouse in Nevada. It is licensed for medical marijuana cultivation and production, and recreational marijuana cultivation and production in Nevada.

Upon being canopied, schedule for Q1 of 2019, the 455,000 square foot facility will be used for cannabis cultivation. It will also be used for the processing, production and high-volume packaging of dry flower, cannabis oils, concentrates and infused products. When Flower One’s greenhouse is completely operational this year, along with its indoor facility, it will be able to produce 140,000 pounds (62,500 kilograms) per year. Its state-of-the-art greenhouse and production facility are strategically situated close to the fast-growing, tourism-driven Las Vegas recreational and medical cannabis market.

Flower One announced this past January a new licensing agreement and Brand Partnership for cannabis-product fulfillment in Nevada. Palms is a California-based, experience-driven cannabis brand. Flower One is now licensed to manufacture, distribute and sell Palms' signature cannabis products to all cannabis retailers in Nevada. This marks the consumer brand's first out-of-State expansion.

Flower One Holdings announced in January another new licensing agreement and Brand Partnership for cannabis-product fulfillment in Nevada. HUXTON is an Arizona-based lifestyle cannabis brand. It is known for its curated, consistent, multi-strain blended products. Flower One is now licensed to manufacture, distribute and sell HUXTON's signature cannabis products to all cannabis retailers in Nevada. HUXTON's three product series, HIFI, RISE, and ZEN, will be available in Nevada dispensaries as pre-rolls and vape pens. They will be branded according to the experience they offer.

In February, Flower One announced a new long-term licensing agreement and brand partnership with CannAmerica Brands Corp. for cannabis-product fulfillment in Nevada. CannAmerica Brands is a Colorado-based, marine-veteran-founded cannabis brand known for its line of top-tier cannabis gummies and edibles. Flower One is now licensed to manufacture, distribute and sell CannAmerica Brands' signature cannabis Fruit Juice Gummies and Super Soft Gummies to all cannabis retailers in Nevada. The agreement represents Flower One's official launch into the edibles market.

Last month, Flower One announced a new long-term licensing agreement and partnership with foremost cannabis technology and hardware brand, Grenco Science (G Pen). Grenco Science (California headquartered) are pioneers in the cannabis hardware space, responsible for engineering the advanced technology behind the internationally-available and ever popular G Pen line of cannabis vaporizers. Flower One is now licensed to sell, distribute and integrate G Pen's proprietary, unique hardware with new cannabis products from its varied portfolio of Brand Partners.

Flower One Holdings, Inc. (FLOOF), closed Tuesday's trading session at $2.01, up 2.03%, on 72,005 volume with 92 trades. The average volume for the last 3 months is 116,524 and the stock's 52-week low/high is $0.879/$2.376.

chart

MedMen Enterprises, Inc. (MMNFF)

Insider Financial, OTC Stock Picks, New Cannabis Ventures, OTC Markets, Penny Stock Hub, GuruFocus, OTC Stock Watch, Stockhouse, 4-Traders, Investing News, The Street, Wallmine, TradingView, Barchart, Stockwatch, Morningstar, MarketWatch, Daily Marijuana Observer, and Investors Hangout reported previously on MedMen Enterprises, Inc. (MMNFF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

MedMen Enterprises, Inc. brings expertise and capital to the cannabis industry. The Company is one of the nation’s largest financial supporters of progressive marijuana laws. MedMen Enterprises owns and operates facilities covering the whole vertical from cultivation to manufacturing to retail in key states, including California, Nevada, and New York. MedMen Enterprises is headquartered in Culver City, California and the Company lists on the OTC Markets Group’s OTCQX.

MedMen Enterprises manages class leading retail stores that sell marijuana and marijuana products. The Company operates a number of dispensaries in the most strategic markets in the nation. It has a fast-growing footprint that includes expansion plans in other important States and also Canada. At present, MedMen has flagship stores in Los Angeles, Las Vegas and New York.

The Company has added ground cannabis flower to its product offerings in the State of New York. At present, its stores in New York offer vaporizer pens, tinctures and gel caps in five different formulations. The addition of ground flower will give its New York medical marijuana patients more product choices in the State’s fast developing marketplace.

MedMen Enterprises earlier announced its expansion into Florida via a proposed acquisition of dispensary and cultivation assets from Treadwell Simpson Partnership and affiliates. MedMen secured prime retail locations with long term leases in Ft. Lauderdale, Miami Beach, West Palm Beach, St. Petersburg and Key West.

MedMen Enterprises also acquired a dispensary and cultivation license and related assets from Florida based Treadwell Simpson Partnership and affiliates (Treadwell Nursery). The License permits MedMen to open 30 (and up to 35 if certain conditions are met) medical marijuana dispensaries in Florida and to conduct cultivation, delivery and manufacturing operations in the State.

In February, MedMen Enterprises announced that it closed its earlier announced acquisition of Kannaboost Technology Inc. and CSI Solutions LLC, collectively referred to as “Level Up,” two vertically-integrated operations in the State of Arizona. The acquisition includes retail locations in Scottsdale and Tempe, and 25,000 square feet of cultivation and production capacity in Tempe and Phoenix. Moreover, the acquisition includes a 40 percent stake in top-selling brand K.I.N.D. Concentrates that is presently distributed in more than 90 percent of the dispensaries in Arizona.

In March, MedMen Enterprises announced that it completed the sale of two properties to Treehouse Real Estate Investment Trust, Inc. with gross proceeds of roughly $33.5 million and net proceeds of about $30.6 million after repayment of debt. The properties consist of a retail storefront in Las Vegas, Nevada and a cultivation, manufacturing and production facility in Desert Hot Springs, California.

Mr. Adam Bierman, MedMen Enterprises’ Chief Executive Officer and Co-Founder, said, “This is our second transaction with Treehouse and we’ve now freed up nearly $49 million to invest directly into our growth initiatives.”

MedMen Enterprises, Inc. (MMNFF), closed Tuesday's trading session at $3.00, down 0.97%, on 1,036,174 volume with 1,356 trades. The average volume for the last 3 months is 1,364,648 and the stock's 52-week low/high is $2.53/$7.57.

chart

AmpliTech Group, Inc. (AMPG)

PennyStocks24, Ascending Stocks, Information Solutions Group, Pumps and Dumps, HoleinOneStocks, HotStockProfits, Wallstreetbuzz, SmallCapVoice, fusionspicks, Jet-Life Penny Stocks, Fortune Penny Stocks, OTC Magic, Trading Wall St, Penny Stock Gainers, Rocking Penny Stocks, Best Stocks Daily, and All Penny Stocks reported earlier on AmpliTech Group, Inc. (AMPG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

AmpliTech Group, Inc. designs, develops, and manufactures custom and standard state-of-the-art RF Low Noise Amplifiers (LNA) and Power Amplifiers (PA). These are for the domestic and international, SATCOM, Space, and Military markets. The OTCQB-listed Company also provides consulting services to assist with any microwave components or systems design problems. AmpliTech Group is based in Bohemia, New York.

The Company has a Joint Venture (JV) Agreement with Trusted Networks, Inc. (TN). The focus of the JV is to develop an affordable mixed signal chipset, which can be used at the server/router level and in mobile PDA applications to provide secure and encrypted communication with the aim of preventing hacking and cyber-attacks. TN is a New York, New York based private company with facilities in Colorado Springs and Nashua, New Hampshire.

AmpliTech’s designs encompass the frequency spectrum from 50 kHz to 40 GHz - eventually providing designs up to 100 GHz. AmpliTech can provide complex, custom solutions for almost any custom requirements presented to it. It can provide contract assembly of customers' own designs.

The Company provides its customers with consulting services for their system development. In addition, AmpliTech provides technical assistance in integration and packaging technologies and microwave sub-systems and amplifier related sub-assemblies.

AmpliTech uses the most modern CAD microwave simulation technology to design and develop from concept to final manufacture of a deliverable product with premier accuracy. The Company expects to release new products targeted at the wireless and satellite markets that will provide advanced technology and performance.

Last month, AmpliTech Group announced the results of its 10-K filing for FY 2018. The Company reported record Revenue of $2.4 million. It succeeded in converting its record backlog, reported in 2018, into record sales.

Revenue increased by $1,016,675 versus FY 2017. This represents an increase of 73 percent. Income from Operations rose by $431,520 versus 2017. Gross Profit Margin was 58 percent in 2018, up from 53 percent in 2017. AmpliTech added to its customer base and has also seen an increase in demand for its legacy products in the Defense and Military sector.

AmpliTech Group, Inc. (AMPG), closed Tuesday's trading session at $0.047, even for the day, on 57,898 volume. The average volume for the last 3 months is 38,347 and the stock's 52-week low/high is $0.0265/$0.075.

chart

Bluestone Resources, Inc. (BBSRF)

Stock Orange, Wallmine, Barchart, OtcStockWatch, Penny Stock Hub, Current Charts, Dividend Investor, Investors Hangout, OTC Markets, MarketWatch, 4-Traders, and Geology for Investors reported earlier on Bluestone Resources, Inc. (BBSRF), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Bluestone Resources, Inc. centers on advancing its 100 percent owned Cerro Blanco Gold and Mita Geothermal Projects in Guatemala. The Company controls the required surface rights for the Mita Geothermal Project and the Cerro Blanco Project. The Cerro Blanco Project is a classic hot springs-related, low sulphidation gold-silver deposit. A mineral exploration and development enterprise, Bluestone Resources is based in Vancouver, British Columbia and lists on the OTC Markets’ OTCQB.

The Mita geothermal resource was discovered in the late 1990’s during gold exploration in southeastern Guatemala. The permitted Mita Geothermal Project is contiguous to Bluestone Resources’ Cerro Blanco Gold Project in Guatemala. It is in southeast Guatemala, about 160 kilometers by road from the capital, Guatemala City.

The Cerro Blanco Project economics and updated mineral resource estimate for Cerro Blanco indicates a strong project with an expected nine-year mine life producing 952,000 ounces of gold and 3,141,000 ounces of silver. Initial capital expenditures estimated in the Preliminary Economic Assessment (PEA) to finance construction and commissioning is estimated at US$170.8 million with all in sustaining cash (AISC) estimated to be US$490 per ounce of gold produced.

The Cerro Blanco Gold Project is not dependent on the Mita Geothermal Project. Nonetheless, Company Management’s belief is that there are potential synergies between the two that enhance the economics of the Cerro Blanco Gold Project beyond what was outlined in the PEA.

Bluestone Resources announced in February 2019 the results of the Independent Feasibility Study prepared in accordance with National Instrument 43-101 (NI 43-101) for its 100 percent owned high-grade Cerro Blanco Gold project. The Feasibility Study demonstrates that the Project represents a strong, fast pay-back, high-grade underground mining operation.

Also in February, Bluestone Resources announced that the 43-101 feasibility study technical report for the Cerro Blanco Gold Project in Guatemala was filed and is available for review under Bluestone's profile on SEDAR at www.sedar.com and on the Company's website at www.bluestoneresources.ca.

Last month, Bluestone Resources announced additional high-grade intercepts from the infill resource drill program at its Cerro Blanco Gold Project. The principal emphasis of the program is to upgrade Inferred Resources identified during the prior drill program completed in 2018. Furthermore, the design of the program is to define new resources along known veins in the mine plan that extend outside of the present resource envelope. The Step-Out drill hole intercepted 201.4 g/t Au and 2,139 g/t Ag over 1 meter at Cerro Blanco - 20 meters outside of the current resource envelope.

Bluestone Resources, Inc. (BBSRF), closed Tuesday's trading session at $0.911, down 0.19%, on 1,840 volume with 5 trades. The average volume for the last 3 months is 9,811 and the stock's 52-week low/high is $0.8064/$1.16.

chart

Molori Energy, Inc. (MOLOF)

Awesome Stock Picks, MarketWatch, 4-Traders, Zacks, OTC Markets, Stockhouse, Streetwise Reports, InvestorsHub, MarketWatch, Seeking Alpha, and Proactive Investors reported previously on Molori Energy, Inc. (MOLOF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Molori Energy, Inc. has present operations in the Texas Panhandle West Field. The Company’s operating team based in Borger, Texas has wide-ranging experience in the oil and gas industry in the Texas Panhandle. Molori Energy's business model is to deliver sustainable growth in shareholder value through focusing on exploiting its existing reserves, commercializing and developing discoveries, and pursuing selective acquisitions.

An oil and gas production business, Molori Energy is based in Vancouver, British Columbia. The Company formerly went by the name Taipan Resources, Inc. In January 2017, it changed its corporate name to Molori Energy, Inc.

The Company’s strategy has been to engage in low-risk well reactivations in the Texas Panhandle to generate steady cash flows. Molori owns a 25 percent Working Interest (WI) in certain leases situated in the bifurcated Texas panhandle, operated by its Texas-based partner Ponderosa Energy, LLC.

Molori Energy has 165 producing (PDP) wells and an inventory of roughly 202 non-producing wells (PDNP) for a total of 367 wells. It is working to RTP (Return to Production) the PDNP wells through performing simple re-works or re-completions.

In 2018, Molori Energy provided an update pertaining to its operations in Moore County and Hutchinson County, Texas. On May 7, 2018, it announced the first of two Letters of Intent (LOIs) to acquire a 100 percent Working Interest (WI) in about 30,000 acres with access to the Red Cave and other formations. The acreage, in Moore, Potter, Carson and Hutchinson counties, is HBP (Held By Production), and includes 8 currently-producing wells.

On May 22, 2018, Molori Energy announced the second LOI for the purchase of a 100 percent WI in an additional 5,100 acres in the Red Cave formation. An 81 acre tract included within the proposed purchase is of significant interest because it adjoins property owned by Adams Affiliates, Inc., (Tulsa, Oklahoma), who successfully drilled greater than 50 Red Cave wells in the past three years. The 81 acre tract also offers 18 drill-ready locations. This 5100 acres is also HBP.

Molori Energy, Inc. (MOLOF), closed Tuesday's trading session at $0.0629, up 31.18%, on 11,053 volume with 5 trades. The average volume for the last 3 months is 17,422 and the stock's 52-week low/high is $0.0186/$0.2689.

chart

Orexo AB (publ) (ORXOY)

Stockaboo, Stockhouse, MarketWatch, Market Screener, Stock2Own, Wallmine, Financial Content, Biospace, Barchart, 4-Traders, Business Wire, Investing Online, Current Charts, OTC Dynamics, OTC Markets, GuruFocus, Stockwatch, and Wallet Investor reported earlier on Orexo AB (ORXOY), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Orexo AB develops improved pharmaceuticals founded on inventive drug delivery technologies. The OTCQX-listed Company is a fully integrated specialty pharmaceutical business. Its focus is chiefly on opioid dependence and pain. Nonetheless, its aim is to also address other therapeutic areas where its competence and technologies can create value. Orexo is headquartered in Uppsala, Sweden.

Orexo’s pipeline consists of projects in varied development phases. The principal therapeutic focus is around addiction in all phases, from prevention to treatment. Its pipeline includes OX382, Phase I - oral formulation of buprenorphine, and OX124, Preclinical phase - Naloxone rescue medication. Additionally, the Company’s pipeline includes OX338, Preclinical phase - new NSAID formulation, and also OX-MPI, Preclinical phase - Inflammation (Gesynta Pharma).

The Company’s primary contemporary market is the U.S. market for buprenorphine/naloxone products, where Orexo commercializes the product Zubsolv®. Other products are commercialized through partners. This includes the sale of Zubsolv outside the U.S.

Vital drivers of growth for the Company include maximizing Zubsolv®’s potential in a worldwide fast growing market. Another vital driver of growth is increasing profitability and cash flow growth with operational leverage achieved in manufacturing. In addition, growth drivers include adding commercial stage products in the U.S. to leverage the commercial infrastructure and advancing the pipeline of internal development projects.

Zubsolv® is a product for the treatment of opioid dependence. It has comparable efficacy and safety and the same active components as previously approved buprenorphine/naloxone sublingual formulations. Zubsolv® offers higher bioavailability, quick dissolve time, preferred menthol flavor, and the widest range of dose strengths. Market access for Zubsolv® significantly improved in 2018. The launch of Zubsolv® in Europe started in June of 2018.

This past January, Orexo announced positive results from the human pharmacokinetic (PK) study OX124-001 in 20 healthy volunteers, assessing the Company's novel naloxone nasal spray formulations intended for opioid overdose reversal. This study was a cross-over, comparative, bioavailability study comparing four development formulations of OX124 to Narcan® Nasal Spray 4mg, the current market-leading naloxone rescue medication in the United States. All formulations of OX124 were well tolerated. They showed considerably higher plasma concentrations of naloxone, sustained duration of elevated plasma concentrations, and equivalent or superior onset time versus Narcan®.

Also in January 2019, Orexo announced that the United States District Court for the District of Delaware issued a final, non-appealable judgment that Actavis's generic Zubsolv products infringe Orexo's U.S. patent No. 8,940,330. The judgment will prevent Actavis from commercializing their infringing generic Zubsolv products in the United States until after September 18, 2032.

Orexo AB (ORXOY), closed Tuesday's trading session at $7.02, even for the day, on 400 volume. The average volume for the last 3 months is 41 and the stock's 52-week low/high is $3.51/$8.95.

chart

Osprey Gold Development Ltd. (OSSPF)

Stock Orange, Stockhouse, InvestorsHub, 4-Traders, OTC Markets, Morningstar, MarketWatch, GuruFocus, Junior Mining Network, Investing News, The Street, Seeking Alpha, and WatchDog Stocks reported earlier on Osprey Gold Development Ltd. (OSSPF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Osprey Gold Development Ltd. centers on exploring five historically producing gold properties in the Province of Nova Scotia. The Company’s flagship project is Goldenville in the historical mining district Goldenville, which is one of eastern Canada’s most significant gold belts. Osprey Gold has the option to earn 100 percent (subject to certain royalties) in all five properties. This includes the Goldenville Gold Project. Osprey Gold Development is headquartered in Vancouver, British Columbia.

The Goldenville Gold Project has an updated NI 43-101 inferred resource, which includes 2,800,000 tonnes at 3.20 g/t gold for a total of 288,000 ounces of gold (2.8 mil tonnes at 4.96 g/t gold for 447,000 ounces of gold uncapped). In addition, Osprey Gold Development is exploring the past producing Lower Seal Harbour, Miller Lake, Caribou, and Gold Lake gold projects.

Osprey entered into a definitive agreement wherein it acquired an option to acquire the Caribou Gold Property from John Logan Enterprises Ltd. With the Option Agreement, the Company may acquire a 100 percent interest (subject to certain royalties) in 16 contiguous mining claims (256 hectares) hosting the past-producing Caribou Property.

The Miller Lake Project is roughly 14 kilometers from Goldenville. It has historic production and limited recent exploration. The Gold Lake Project is approximately 70 kilometers northeast of Halifax. It was discovered in 1867 with minor production occurring in the late 1800’s.

The Caribou Gold property is 80 kilometers northwest of Halifax, Nova Scotia and 10 kilometers south of the rural community of Upper Musquodoboit, in Halifax County. The Caribou property contains an historic gold deposit that was intermittently mined between 1869 and 1955.

The Lower Seal Harbour project is in Guysborough County, Nova Scotia. This property is about 35 kilometers from Goldenville. Gold at Lower Seal Harbour is found in the veins and the host rocks.

Osprey Gold provided this past November more results from its exploration program at the Caribou Gold Project. The results provide continued evidence of lower grade disseminated mineralization within the host sediments, around the historically sampled high grade veins. The best reported intercept was hole CM87-23 reporting 70.57 meters (m) of 1.58 grams per tonne gold (g/t Au), or 0.80 g/t Au if utilizing a 70 g/t Au grade cap. Seven holes were sampled from four key areas for a total of 395 samples submitted for analysis.

At the end of December 2018, Osprey Gold reported that it closed its earlier announced non-brokered private placement of 1,334,000 flow through units (FT Units) of Osprey Gold at a price of $0.075 per unit, for total proceeds of $100,050. Each unit comprises one common share and one-half of one share purchase warrant, each whole warrant entitling the holder to purchase an additional common share at a price of $0.12 per share for a period of 18 months from date of issuance. Net proceeds of the private placement will be used for exploration and advancement of the Company’s exploration projects in Nova Scotia and general working capital.

Osprey Gold Development Ltd. (OSSPF), closed Tuesday's trading session at $0.04, even for the day, on 6,600 volume. The average volume for the last 3 months is 18,517 and the stock's 52-week low/high is $0.028/$0.0765.

chart

Abattis Bioceuticals Corp. (ATTBF)

Greenbackers, Promotion Stock Secrets, InvestorIntel, Stockgoodies, Cannabis Financial Network News, PennyStocks24, CFN Media Group, Goldman Small Cap Research, and Information Solutions Group reported previously on Abattis Bioceuticals Corp. (ATTBF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Abattis Bioceuticals Corp. is a life sciences and biotechnology company based in Vancouver, British Columbia (BC). The Company aggregates, integrates and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. It has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. Abattis Bioceuticals also has an operations office in Langley, BC.

The Company’s brands include Vergence Naturals™. Additionally, Abattis is working to acquire exclusive intellectual property (IP) rights to agricultural technologies to be utilized in the extraction and processing of botanical ingredients and compounds.

The Company has, through its operations and wholly-owned subsidiaries, a broad array of capabilities. These include cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal marijuana markets in North America.

Abattis Bioceuticals has a 90 percent ownership interest in Gabriola Green Farms, Inc. Gabriola is a BC company. Gabriola has applied for a license to produce (LP) under the Access to Cannabis for Medical Purposes Regulations (ACMPR) on Gabriola Island, one of the gulf islands in the Strait of Georgia off the coast of BC. Currently, Gabriola has plans for an approximately 26,000 square-foot production facility to produce medical-grade marijuana located on 18 acres in the agricultural land reserve on Gabriola Island, BC.

Abattis is continuing its development work on a hemp-infused cannabinoid-rich, THC-free craft beer with Faculty Brewing Co. It is also continuing its development work on nanoemulsified and liposomal platforms for transmucosal delivery of cannabinoid-rich hemp oil with the University of British Columbia.

Abattis Bioceuticals has an investment in XLABS Therapeutics (ONT), Inc. Abattis and XLABS will be launching a new cannabis laboratory in Belleville, Ontario, to serve Ontario’s increasing cannabis sector.

This past November, Abattis Bioceuticals announced that it acquired Select Strains. Select Strains has a portfolio of greater than 140 laboratory-tested craft cannabis strains. Abattis hopes to leverage these via licensing arrangements, clone fulfillment, tissue culture and strain patenting services and ultimately through its late-stage ACMPR licensed producer applicant, Gabriola.

This month, Abattis Bioceuticals announced that, further to its new release dated December 7, 2018, it entered into a definitive share exchange agreement with 1157016 B.C. Ltd., d/b/a NutriVida, a private arm’s length company, whereby Abattis will acquire 100 percent of the issued and outstanding common shares of NutriVida. NutriVida has been well-known in the fertilizer and cultivation industry for the past 25 years. It has extensive knowledge and experience in researching, innovating, manufacturing, and selling all-natural, bio-safe, fertilizers and plant nutrients.  

Abattis Bioceuticals Corp. (ATTBF), closed Tuesday's trading session at $0.0345, up 11.29%, on 374,324 volume with 76 trades. The average volume for the last 3 months is 715,641 and the stock's 52-week low/high is $0.017/$0.20.

chart

Natural Health Farm Holdings, Inc. (NHEL)

4-Traders, Street Insider, Morningstar, Simply Wall St, InvestorsHub, OTC Markets, GuruFocus, MarketWatch, Stockopedia, Stockhouse, Market Exclusive, last10k, Barchart, and CapitalCube reported previously on Natural Health Farm Holdings, Inc. (NHEL), and today we chose to report on the Company, here at the QualityStocks Daily Newsletter.

Natural Health Farm Holdings, Inc. is a biotechnology company working to form a complete healthcare one-stop shop based on natural or naturopathic products. Since November 2017, the Company has developed and started to commercialize the web-based Naturopathic Learning Management System to enable consumers and distributors to be educated on health-related aspects of different diseases and nutritional consulting services. Natural Health Farm Holdings is based in Las Vegas, Nevada.

The Company provides online nutritional consultation services. It does so through offering a web-based naturopathic learning management system. This system educates their customers on general wellbeing. Natural Health Farm’s chief activities are in retailing nutritional supplements, organic foods and health-care related products.

Through its subsidiary, NHF International Limited, Natural Health Farm specializes in biotechnology research & development, and a retail business. It has a chain of manifold retail & franchise outlets located throughout Malaysia and other nations. These include Singapore, Brunei, Philippines, China, Hong Kong and the United States.

Earlier this month, Natural Health Farm Holdings, announced that it executed a term sheet to acquire all of the issued and outstanding shares of Natural Tech R&D Sdn Bhd, a BioNexus accredited research and development company in Malaysia. With this agreement, Natural Health Farm Holdings shall acquire 100 percent of Natural Tech R&D’s outstanding shares for USD 1 Million.

Last week, Natural Health Farm Holdings announced that it executed a term sheet to acquire all of the issued and outstanding shares of Excel Herbal Industries Sdn Bhd. Excel Herbal is a nutraceutical biotechnology manufacturing, organic food and health supplements enterprise in Malaysia.

With this agreement, Natural Health Farm Holdings shall acquire 100 percent of Excel Herbal Industries’ outstanding shares for USD 2 Million. The anticipation is that Natural Health Farm Holdings shall complete the due diligence process and close the transaction within 60 calendar days from the term sheet date.

Natural Health Farm Holdings, Inc. (NHEL), closed Tuesday's trading session at $0.33, up 8.20%, on 162,514 volume with 59 trades. The average volume for the last 3 months is 297,592 and the stock's 52-week low/high is $0.17/$6.00.

chart

Organigram Holdings, Inc. (OGRMF)

Penny Stock Tweets, Wallet Investor, Marijuana Stock, Marijuana Stocks Report, CFN Media Group, Investor Place, Wealth Daily, Daily Marijuana Observer, TradingView, Microcap Daily, The Street, Cannabis Financial Network News and Money Morning reported on Organigram Holdings, Inc. (OGRMF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Organigram Holdings, Inc.’s focus is on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada. The Company’s wholly-owned subsidiary, Organigram, Inc., is a licensed producer of cannabis and cannabis-derived products in Canada. Organigram has developed a portfolio of brands. These include The Edison Cannabis Company, Ankr Organics, Trailblazer and Trailer Park Buds. The Company’s head office, production facility, and Research and Development (R&D) are in Moncton, New Brunswick.

Organigram has collaborations with healthcare experts and academic institutions. It invests in medical education, outreach, as well as research for the use of cannabinoids as a first line of treatment. Organigram provides a diverse assortment of genetics and product types. These cater to the individual needs of each client. The Company offers a reliable supply of premier quality, industry-leading strains to match individuals’ personal needs.   

Organigram is undergoing a production-facility expansion. This expansion will more than triple the size of its operations. The multi-million-dollar project will meet the increasing needs of its medical patient base, and prepare it for the legal, adult-recreational marijuana market.

Moreover, the Company’s plans include a production-capacity increase from approximately 5,200 kilograms (kg) annually to greater than 25,000 kg annually. In addition, plans include the acquisition of a third building at 55 English Drive for future expansion, next to the present campus.

This week, Organigram Holdings announced it entered into an agreement with 1812 Hemp, a New Brunswick based industrial hemp research company to secure supply and support research and development on the genetic improvement of hemp via traditional plant breeding methods. 1812 Hemp is centered on further developing a line of Canadian cultivars (specific varieties of plants cultivated to enhance desirable qualities) of high cannabidiol (CBD) yielding hemp for the Canadian climate. With this agreement, Organigram will have access to a secure supply of hemp flower that contains significant levels of cannabidiol (CBD cultivars ranging from 4 percent to 8 percent).

Additionally, this week, Organigram Holdings announced it made changes to its compassionate care model by developing OrganiCare. This is a program designed to improve access to medical cannabis for low-income patients. Effective immediately, patients who earn an annual income of less than $35,000 per year qualify for OrganiCare, Organigram’s new program, which offers qualified patients a 30 per cent price reduction on all dried cannabis products and oils. The Company's Compassionate Care Program was voted best in Canada at the Canadian Cannabis Awards in 2017.

Organigram Holdings, Inc. (OGRMF), closed Tuesday's trading session at $7.30, up 3.25%, on 1,013,870 volume with 2,292 trades. The average volume for the last 3 months is 864,861 and the stock's 52-week low/high is $2.57/$7.47.

chart

Kalytera Therapeutics, Inc. (KALTF)

Penny Stock Hub, Dividend Investor, Proactive Investors, YCharts, Capital Network, OTC.Watch, Investing, The Street, OTC Markets, InvestorsHub, 4-Traders, Stockhouse, Stockwatch, Marketbeat, Investors Hangout, and Barchart reported earlier on Kalytera Therapeutics, Inc. (KALTF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Kalytera Therapeutics, Inc. is pioneering the development of a next generation of cannabinoid therapeutics. The Company is working to establish a leading position in the development of novel cannabinoid medicines for an array of important unmet medical needs, with an initial focus on Graft versus Host Disease (GvHD). Kalytera Therapeutics has its U.S. headquarters in Novato, California. A clinical-stage pharmaceutical company, its research facility is in Israel.

Kalytera Therapeutics is also developing a new class of proprietary cannabidiol (CBD) therapeutics. Its intention is to explore the use of CBD, a non-psychoactive cannabis constituent. The Company is working to advance a portfolio of synthetic, non-psychoactive cannabis-like molecules. Additionally, Kalytera will center on orphan conditions, with the aim of generating data in humans that may support follow-on studies in major conditions.

Kalytera received approval from the Institutional Review Board (IRB) at one of two clinical sites in Israel. This is to begin a Phase 2 study to evaluate cannabidiol (CBD) for the prevention of GvHD. The proposed study is a Phase 2, open label, multicenter trial. The trial is to evaluate the pharmacokinetic profile, safety, and efficacy of numerous doses of CBD for the prevention of GvHD following allogeneic hematopoietic cell transplantation (HCT). The proposed study will take place at the Rabin Medical Center, Beilinson, and the Rambam Health Care Campus, Haifa, in Israel.

The expectation is that Kalytera’s continuing Phase 2b clinical study evaluating the use of CBD in the prevention of GVHD will be completed early this year. Upon completion of the Phase 2b clinical study, Kalytera will begin preparations for the pivotal Phase 3 clinical study that will be required for Food and Drug Administration (FDA) approval.

The work that Kalytera Therapeutics is doing in GVHD consists of two separate product development programs. One is a program evaluating CBD for the prevention of acute GVHD. A separate program is evaluating CBD for the treatment of acute GVHD. The Company’s program in prevention of acute GVHD is more advanced than is the program in treatment of acute GVHD.

Kalytera Therapeutics is the exclusive licensee of two issued U.S. patents covering the use of CBD in the prevention and treatment of GVHD. It is also the exclusive licensee of pending patent applications in other jurisdictions for the use of CBD in the prevention and treatment of GVHD.

Recently, Kalytera Therapeutics announced positive interim data from its continuing Phase 2 clinical study evaluating cannabidiol (CBD) for the prevention of acute graft versus host disease (GVHD) following bone marrow transplant. Interim data from the initial 12-patient cohort support the following key findings to date.

No patients receiving oral CBD at the lowest study dose of 75 mg twice daily (BID) have developed grades 3 or 4 acute GVHD. One patient developed grade 2 acute GVHD, the least serious form of the disease. CBD has demonstrated a good safety and tolerability profile, with no significant adverse events relating to its use.

Kalytera Therapeutics, Inc. (KALTF), closed Tuesday's trading session at $0.0587, up 2.26%, on 128,603 volume with 17 trades. The average volume for the last 3 months is 230,840 and the stock's 52-week low/high is $0.0361/$0.275.

chart

Know Labs, Inc. (KNWN)

Amigo Bulls, Venture Line, MarketWatch, Simply Wall St, Street Insider, Wallet Investor, Stockopedia, Investors Hangout, TradingView, Business Wire, 4-Traders, YCharts, Open Insider, Marketbeat, last10k, Stockwatch, High Rising Stocks, Dividend Investor, OTC Markets, Spotlight Growth, Insider Tracking, Stockhouse, Insider Monkey, and InvestorsHub reported previously on Know Labs, Inc. (KNWN), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Know Labs, Inc. is developing a new technology platform that measures blood glucose non-invasively. The Company invented a pioneering technology called Bio-RFID, which will provide information to consumers about their health and wellness. In addition, Know Labs uses its proprietary ChromaID technology to identify unique molecular signatures in materials. OTCQB-listed, the Company formerly went by the name Visualant, Incorporated. It changed its name to Know Labs, Inc. in May of 2018. Know Labs is based in Seattle, Washington.

The Company develops technology platforms that harness light and radio waves to uncover distinct insights about the world. Its technology directs electromagnetic energy through a substance or material to capture a unique molecular signature.

Know Labs refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio- RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye.

ChromaID and Bio-RFID scanner modules can be integrated into a variety of mobile or bench-top form factors. This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or large and expensive lab-based tests.

Know Labs has its UBAND™ real time wearable calorie counter wrist band. The Calorie Counter UBAND is built upon the Company’s recent invention that detects blood glucose non-invasively.

Last week, Know Labs released a white paper detailing the results of an experiment using the Company’s Bio-RFID™ technology to detect varying blood-glucose levels in the human body. The experiment used a tissue phantom mimicking a blood/skin/muscle ratio of roughly 5%/10%/85% respectively to measure varying amounts of glucose in the blood. The experiment produced successful results with the sensor system showing strong signal response and linearity between the differing glucose levels.

The white paper was co-authored by Mr. Phil Bosua, Chief Executive Officer of Know Labs, and Mark Tapsak, Ph.D., who in addition to his professorial roles is also Interim Assistant Vice President and Dean of Graduate Studies and Research at Bloomsburg University.

Know Labs, Inc. (KNWN), closed Tuesday's trading session at $1.38, up 6.15%, on 10,031 volume with 24 trades. The average volume for the last 3 months is 59,425 and the stock's 52-week low/high is $0.231/$5.75.

chart

biOasis Technologies, Inc. (BIOAF)

Zacks, OTC Markets Group, Venture Beat, PennyStocks24, Tailwinds Research Group, Midas Letter, Capital Cube, 4-Traders, Stockwatch, SmallCapFinancialWire, YCharts, and Uptick Newswire reported earlier on biOasis Technologies, Inc. (BIOAF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

biOasis Technologies, Inc. concentrates on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB). The delivery of therapeutics across the BBB represents the single greatest challenge in treating neurological disorders. The OTCQB-listed Company is developing and commercializing the xB3 platform, its proprietary blood-brain barrier delivery technology, to address unmet medical needs in the treatment of central nervous system (CNS) diseases and disorders. A biopharmaceutical business, biOasis Technologies is based in Richmond, British Columbia.

The Company’s Transcend Platform is currently available to be licensed by biotechnology and pharmaceutical companies for the advancement of their neurotherapeutic programs. The Transcend Platform has realized a significant high level of success in dozens of studies at more than 20 third-party institutions and pharmaceutical companies. biOasis has attained full patent protection for its Transcend group of peptide carriers and linkers. The Transcend-peptide platform is presently referred to as the above-mentioned xB3 platform. It is part of the Company’s patented portfolio that is transforming therapeutic brain-drug delivery.

The Transcend Platform consists of a divers set of peptide carriers and linkers. These, together, provide transport solutions for an assortment of CNS therapeutics. These include monoclonal antibodies, enzymes, small molecules, and different kinds of gene therapies. Transcend is based on the naturally occurring human transport protein, melanotransferrin, also called MTf, CD228 and p97. MTf is found at low concentrations in the blood.

MTf is able to cross the BBB through a process named Receptor Mediated Transcytosis where MTf molecules attach to receptors on the cells of the BBB and is subsequently pulled through the cells and into the brain. With biOasis Technologies’ proprietary Transcend carrier, the MTf protein can be attached to therapeutics of different sizes and kinds.

biOasis Technologies and BioAgilytix have a strategic collaboration to partner on the development and validation of bioanalytical methods to support and advance the xB3 TM-001 program, BiOasis’ lead candidate to treat HER2+ brain cancer, to investigational new drug (IND) submission and into the clinic. BioAgilytix is a foremost provider of contract bioanalytical testing services with a specialization in large molecule bioanalysis.

This past November, biOasis Technologies announced data using its lead investigational candidate xB3-001 in an advanced positron emission tomography and computed tomography (PET/CT) imaging study in non-human primates suggest selective peripheral distribution. Additionally, this data indicates penetration of the lymphatic system with xB3-001.

In collaboration with Invicro LLC., whole-body distribution of xB3-001 was examined in the study employing advanced PET/CT imaging in non-human primates. Data from the study suggest a more selective peripheral distribution pattern for xB3-001 versus trastuzumab alone. Notably, the data also indicate that the xB3 platform has the potential to penetrate the lymphatic system as shown by the accumulation of xB3-001 in the cervical lymph nodes, which is not seen in trastuzumab alone.

This month, biOasis Technologies announced a joint research collaboration with a top pharmaceutical company. With this Agreement, biOasis will manufacture an antibody-peptide conjugate containing its xB3 peptide for in vivo measurement in the CNS, enabling direct evaluation of the xB3 platform’s delivery capabilities.

biOasis Technologies, Inc. (BIOAF), closed Tuesday's trading session at $0.2674, up 0.91%, on 2,000 volume with 3 trades. The average volume for the last 3 months is 10,638 and the stock's 52-week low/high is $0.2096/$0.6619.

chart

Geospatial Corp. (GSPH)

Penny Sleuth, Micro Cap Research, InvestorsHub, Market Screener, 4-Traders, Morningstar, MarketWatch, PR Newswire, GuruFocus, HotStockChat, YCharts, Wallet Investor, SmallCapVoice, Trading View, The Street, last10k, and Simply Wall St reported earlier on Geospatial Corp. (GSPH), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Geospatial Corp. is a leading innovator of asset management/analytics/mapping software and 3D mapping technologies. The Company utilizes integrated technologies to establish the accurate location and position of underground pipelines, conduits, and also other underground infrastructure data. This allows Geospatial to create accurate three-dimensional (3D) digital maps and models of underground infrastructure. Geospatial is headquartered in Sarver, Pennsylvania.

The Company has new Quality Assurance (QA) and Installed Locational Integrity Management (ILIM) programs for underground pipelines. Geospatial provides complete QA programs and ILIM programs for underground pipelines and conduits installed through Horizontal Directional Drilling (HDD) methods irrespective of depth, material, or soil conditions. The service addresses the need for accurate 3D mapping of critical pipeline segments, which exceeds regulatory requirements and supports integrity and reliability demands.

The Company provides integrated data acquisition technologies. These technologies accurately locate and map underground and aboveground infrastructure assets. This includes pipelines and surface features via Geospatial’s GeoUnderground Cloud-Based Portal. The design of GeoUnderground is around the Google Maps API.

GeoUnderground is the Company’s cloud-based Geographic Information System (GIS) platform. It provides clients with a total solution to their underground and aboveground asset management needs. Geospatial uses a collection of data acquisition tools. The Company cost-effectively maps most pipelines to an accuracy of less than 10 cm (3.9 inches).

GeoUnderground is a strong Cloud-Based GIS database. The database enables users to view and use this 3D pipeline mapping information securely from any desktop or mobile device. Geospatial is integrating Blockchain technology with GeoUnderground. This will provide a cloud-based locational software platform permitting energy companies a secure way to manage contracts, assure provenance, and track asset maintenance.

Last week, Geospatial announced that Kerr Engineered Sales and Geospatial entered into a sales and marketing agreement to provide underground mapping solutions, data acquisition and software solutions across the North East and Mid-Atlantic regions. Kerr Engineered Sales has been selling integrated solutions to major oil and gas transmission and distribution companies for decades. It has established a strong reputation representing many of the best technologies within the energy industry.

Geospatial Corp. (GSPH), closed Tuesday's trading session at $0.0191, up 19.37%, on 500 volume with 1 trade. The average volume for the last 3 months is 22,569 and the stock's 52-week low/high is $0.0135/$0.048.

chart

The QualityStocks Company Corner

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (PQEFF).

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) is a Canadian-registered, publicly traded company engaged in the development and implementation of proprietary technologies for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits. The company is focused on oil sands exploration and production on mineral leases in Vernal, Utah, and in expanding production capacity at its Asphalt Ridge heavy oil extraction facility in Utah.

Petroteq Energy’s patent-pending application is a closed-loop, solvent-based process, which results in significantly lower per-barrel production costs than those incurred with traditional hot water-based oil sands extraction technologies. This green technology utilizes a small, modular footprint, produces no greenhouse gases, requires no high temperatures, leaves only clean dry sand, and could be deployed to unlock heavy oil deposits located around the world.

The Company’s Asphalt Ridge mineral lease on 2,500-plus acres in northeastern Utah features a large contingent oil sands resource base with an estimated 87 million barrels of oil equivalent. In 2015, the company produced 10,000 barrels of oil from the Utah location and plans to increase production are underway. Utah holds over 32 billion barrels of undeveloped oil sands resources, which are also known as “oil-wet” deposits containing a mixture of sand and a dense, extremely viscous form of petroleum referred to as bitumen or tar. A recent upswing in developing domestic energy sources has intensified interest in technological advances such as Petroteq’s Clean Oil Recovery Technology (CORT) System.

The Company continues to evaluate the development of other medium to heavy oil exploration, production and recovery projects on a global basis through a variety of structured agreements. These opportunities or other arrangements with private and governmental entities that utilize Petroteq Energy’s proprietary licensed technologies are expected to generate a significant return on investment.

The Company’s management team, board of directors and officers form an invaluable cross-section of industry leaders with extensive experience ranging from chemical engineering and solvent research, business development, international project management, entrepreneurial achievements, and senior management for global energy companies in North America and the Middle East. This impressive knowledge base covers both conventional and unconventional oil and gas projects and production, both in upstream and downstream industry sectors.

Petroteq Energy is also participating in a blockchain initiative aimed at solving the global transaction needs of the oil and gas industry through the development of PetroBLOQ. PetroBLOQ recently joined the Enterprise Ethereum Alliance (“EEA”), the world’s largest open-source blockchain initiative. Membership with the 200-member EEA represents a wide variety of industries and offers 14 industry-focused, member-driven working groups.

“Joining this community of forward-looking enterprises and blockchain innovators is an important step for PetroBLOQ as we develop transformative solutions for the oil and gas industry,” said Petroteq Energy Chairman Alex Blyumkin.

In addition, Petroteq has joined the American Petroleum Institute (API). The API is the only national trade association representing all facets of the oil and natural gas industry, promoting safety across the industry globally and influencing public policy in support of a strong, viable oil and natural gas industry.

“API has led the development of operating standards for our industry, and we look forward to contributing our experience with oilfield technologies in addition to introducing our PetroBLOQ platform to its members throughout the supply chain,” Blyumkin previously stated.

Petroteq Energy Inc. (PHVAF), closed the day's trading session at $0.3299, off by 2.97%, on 43,124 volume with 28 trades. The average volume for the last 3 months is 129,214 and the stock's 52-week low/high is $0.2896/$1.43.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries, today released a new, short video demonstrating the ability of the Company's proprietary Ultra Shear Technology (UST™) platform to create water-soluble CBD oil that disperses instantly, resulting in improved dosing effectiveness, enhanced absorption, and more aesthetically-pleasing products when added to carbonated soft drinks, vitamin-infused sports drinks, and beer. Link to video: PBI UST CBD Video 040219.

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed the day's trading session at $3.64, up 1.68%, on 18,928 volume with 33 trades. The average volume for the last 3 months is 15,038 and the stock's 52-week low/high is $1.52/$4.09.

Recent News

chart

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Monday provided a clinical, corporate and financial update for the year ended December 31, 2018. Among other highlights, Genprex reached various milestones in 2018 and early 2019 which included completing its initial public offering (“IPO”) and listing of common stock on NASDAQ Capital Market, completing a $10 million private placement, and securing a contract with Accenture to provide clinical data management services to help fast-track the clinical development of Oncoprex(TM). To view the full press release, visit: http://nnw.fm/x8Vst.

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed the day's trading session at $1.68, up 2.13%, on 24,079 volume with 66 trades. The average volume for the last 3 months is 47,961 and the stock's 52-week low/high is $0.95/$19.45.

Recent News

chart

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

NetworkWire: Wildflower Brands Inc. (CSE: SUN, OTC: WLDFF) (the “Company”) is pleased to have entered into a delivery fulfillment agreement with HelloMD. Wildflower Brands has been expanding in multiple lines of businesses, and the monetization of its California operations and licenses continues with this agreement.

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

  • Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
  • King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
  • Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company Eaze.com to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed the day's trading session at $0.557, up 1.88%, on 19,015 volume with 15 trades. The average volume for the last 3 months is 14,907 and the stock's 52-week low/high is $0.009/$1.139.

Recent News

chart

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF)

The QualityStocks Daily Newsletter would like to spotlight Therma Bright, Inc. (OTC: THRBF).

Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF), a medical device technology provider focused on addressing dermatological needs in the multi-billion-dollar cosmeceutical (the convergence of cosmetic and pharmaceutical products) industry, offers relief for insect and marine life bites and stings, which is especially relevant as spring weather patterns transition into increasingly wet and humid conditions. NOTE TO INVESTORS: The latest news and updates relating to THRBF are available in the company’s newsroom at http://nnw.fm/THRBF. Also today, was featured today in the 420 with CNW by CannabisNewsWire. Recreational marijuana has been legal in Colorado since 2012, but the people who buy legal pot have been having a hard time finding where they can consume their purchase. This is now set to change if a bill that has been approved by a House Committee eventually gets the nod from the entire State Assembly and Senate.

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) is a medical device technology provider focused on addressing dermatological needs in the multi-billion-dollar cosmeceutical industry. The company’s effective, non-invasive and pain-free skin care is based on proprietary technology which has received Class II medical device status from the U.S. Food and Drug Administration.

Therma Bright’s portfolio includes products, devices and treatments that have both cosmetic and medicinal or therapeutic benefits, such as for relief of pain, itch and inflammation resulting from more than 20,000 types of insect and marine life bites and stings, including bees, wasps, hornets, mosquitos, black flies and jellyfish.

The Company’s current focus is to market its products online through various social media networks, and to eventually re-establish relationships with major North American and Global retailers.

Products

The company currently has two products on the market and another in the research and development phase:

InterceptCS™ is a thermal therapy device for the treatment and prevention of cold sores caused by the herpes simplex Type 1 virus*. Symptoms typically include sores around the mouth and lips which InterceptCS™ treats by application of controlled topical heat with no risk of burning the skin. When used at the first sign of an oncoming cold sore application of InterceptCS™ can prevent symptoms from developing. Infrared energy and light from the device penetrate the skin killing cells infected with the virus.

InterceptCS™ is available without prescription and comprises a battery powered ergonomic hand-held unit and a disposable single-use treatment activator. Therma Bright has completed prototyping of multi-use activators for InterceptCS™. The company plans to bring to market 5, 10 or 20 multi-use activations at prices that will offer customers greater value than the current single-use activator.

The other Therma Bright product currently under development is TherOZap™, a next generation thermal therapy device powered by the company’s core technology, which is approved by the FDA as a Class II medical device for the relief of the symptoms of insect bites. Therma Bright is testing a new easier-to-use prototype of the device for effectiveness against Zika virus and other diseases carried by mosquitos. Once the technology proves effective, Therma Bright intends to seek regulatory approvals and extend the prototype enhancements to a new commercial version of TherOZap™.

Cannabis

Therma Bright is also conducting research and development on a unique thermal therapy device that would incorporate medical grade cannabis or cannabidiol (“CDB”) sourced from hemp as a cream or gel to provide relief of back, knee and other joint pain. In preparation, the company has incorporated a wholly owned subsidiary to hold any technology for use or application of cannabis. Once approvals are secured, the company plans to sell the device through licensed cannabis producers or retailers across Canada and in international markets where use of cannabis has been legalized. The company has initiated trademark and patent protection for its thermal therapy technology incorporating medical cannabis. Therma Bright has indicated it will seek an acquisition to help further development of this product.

Market Opportunity

A report by market intelligence firm Mordor Intelligence put the global cosmeceuticals market at a value of nearly US$47 billion in 2017 and projects it to be worth more than $80 billion by 2023, growing at a rate of almost 9.5 percent annually. Medical research estimates that somewhere between 20 percent and 40 percent of the population suffer occasional cold sore outbreaks. In Canada those figures would mean five to 10 million people, and in the U.S. some 40 million to 80 million, with recurring cold sores, representing a substantial potential market for Therma Bright.

Management

Rob Fia serves as Therma Bright chairman and CEO. Fia has extensive contacts in the investment community and the financial sector as well as knowledge of various Canadian stock exchange listing processes and requirements. His 18 years in the investment business has included equity research and advising promising early stage companies on corporate finance. Therma Bright CFO Victor Hugo is a senior financial analyst at Marrelli Support Services Inc., for which he provides CFO, accounting, regulatory compliance, and management advisory services to companies listed on the TSX, TSX Venture Exchange and other Canadian and US exchanges.

**Based on double blind placebo study, the InterceptCS™ is approved by Health Canada for the claim “For prevention of cold sores when used within 3 hours of the onset of the prodrome.” The InterceptCS™ is not approved by the United States FDA or any claim of clinical indication, clinical efficacy, and/or cure or prevention of disease.

Therma Bright, Inc. (OTC: THRBF), closed the day's trading session at $0.0254, even for the day, on 1,000 volume. The average volume for the last 3 months is 1,958 and the stock's 52-week low/high is $0.009/$0.028.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) — is pleased to announce that Jon Paul, a veteran senior corporate finance executive and certified public accountant, has been appointed as PLUS’ Chief Financial Officer reporting to PLUS co-founder and CEO Jake Heimark. The Company also announces that Craig Heimark has resigned as the Chief Financial Officer effective immediately and has been appointed as the Chief Strategy Officer, and will remain as Chairman, Secretary and a Director.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed the day's trading session at $4.345, off by 2.36%, on 95,271 volume with 192 trades. The average volume for the last 3 months is 78,924 and the stock's 52-week low/high is $2.81/$6.008.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) is now most definitely on the radar of the investment community. In February, NYC-based investment bank Jefferies initiated coverage of the stock with a ‘Buy’ recommendation (http://nnw.fm/wC4Lm). NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://nnw.fm/TGODF. Also today, was featured today in the 420 with CNW by CannabisNewsWire. Recreational marijuana has been legal in Colorado since 2012, but the people who buy legal pot have been having a hard time finding where they can consume their purchase. This is now set to change if a bill that has been approved by a House Committee eventually gets the nod from the entire State Assembly and Senate.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $3.53, off by 2.49%, on 796,457 volume with 1,157 trades. The average volume for the last 3 months is 1,405,300 and the stock's 52-week low/high is $1.607/$7.894.

Recent News

chart

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)

The QualityStocks Daily Newsletter would like to spotlight Green Growth Brands Inc. (OTCQB: GGBXF).

Green Growth Brands Inc (OTCQB: GGBXF) was highlighted today in a publication from MarijuanaStocks.com, examining how the marijuana stock market has been booming over the course of the past few years as a result of the sheer excitement surrounding the cannabis industry. Any investor who paid attention to the cannabis sector knows that companies responsible for growing cannabis have always rested at the top of the market.

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) is a lifestyle-oriented cannabis and cannabidiol (“CBD”) consumer products company with a portfolio of lifestyle brands customized to connect specific, like-minded customers. Each Green Growth Brand provides the best quality products within a retail experience that appeals to users in an environment that is emotionally branded and easy to navigate.

In the next five years, the cannabis industry will generate more than $28 billion of new revenue from an estimated 14 million new customers, according to Ackrell Capital’s 2018 Cannabis Investment Report. Meanwhile, Hemp Business Journal projects that the CBD market will increase 8x to $3 billion by 2021, up from $200 million in 2017. Green Growth Brand intends to dominate in these markets with a lineup up products grown, manufactured and presented with the highest quality standards in mind.

Products under the Green Growth Brand umbrella include:

  • CAMP: A kiosk-type store where consumers can experience beautifully crafted lifestyle products that enhance one’s journey to self-discovery.
  • Seventh Sense: A CBD-infused body care collection crafted from the finest botanicals and fragrances on earth. Created to maximize the properties and aromatics of each ingredient, Seventh Sense natural products are CBD-infused botanical therapy.
  • Meri+Jayne: Fiercely authentic and wholly unapologetic, Meri+Jayne is a youthful, full-on celebration of what makes each person unique. Expect the unexpected when it comes to this mix of amazing products.
  • Green Lily: A place for women to explore a new world of wellness. With advice on every product, from efficacy to usage, Green Lily guides guests through beautiful new ways to experience cannabis and CBD.
  • The +Source: Located in Las Vegas and Henderson, Nevada, The+Source dispensaries operated by Green Growth Brands serve both medical patients and retail customers. Green Growth Brands also operates a grow and production facility in Post, Nevada, and recently entered into definitive agreements to acquire a Pahrump, Nevada, cultivation facility.
  • XanthicBiopharms is the owner of valuable intellectual property that turns THC(Tetrahydrocannabinol) and CBD into a water-soluble substance. As a result of combining Green Growth Brands and Xanthic, this technology is being used to create incredible new products.

Business Strategy

Green Growth Brands has identified numeroushitches in the current cannabis retail space. The company intends to counter these challenges and provide a customer experience ripe with a friendly staff, in-stock assortments, efficient operations and more. The company’s retail partners provide distribution opportunities within 4,000 stores, as well as robust and established digital platforms to best reach the modern consumer.

Management

Green Growth Brands brings together a collection of expert retailers, scientists, botanists, developers, artists and business leaders for the benefit of building community. Led by an executive management team steeped in decades of experience with several of America’s most successful brands, including Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, Limited Brands and Designer Shoe Warehouse, Green Growth Brands is uniquely positioned to create memorable brands, retail experiences, and quality products for the emerging cannabis industry.

Chief Executive Officer Peter Horvath heads strategy and execution across all company channels, and previously took shoe retailer DSW public on the NYSE at $1.5 billion. As a dynamic, creative brand leader, team builder, and specialty retail veteran with deep roots in finance, Horvath’s unique ability to understand the big picture while never missing the subtle details is a critical factor in Green Growth Brands’ success and brand popularity among customers.

Chief Marketing Officer Scott Razek is a brand strategist, storyteller and strategic marketer. Razek‘s 25 years of experience in brand building, product development and customer experience focus are a key differentiator for the Green Growth Brands portfolio.

CAO Ed Kistner brings 33 years of multifaceted experience at leading retail businesses, notably in finance, merchandise planning, operations and stores. His well-rounded experiences in fast-changing environments position Kistner to be the architect of the operational execution at Green Growth Brands.

CSO Kellie Wurtzman brings significant retail leadership to Green Growth Brands with a proven track record of leading high-performance stores and teams across multiple retail sectors. Her unmatched experience in identifying and supporting developing business opportunities is ideal for evolving the cannabis industry and will be instrumental in expanding operations at Green Growth Brands.

Headquartered in Columbus, Ohio, Green Growth Brands is traded on the Canadian Securities Exchange and on the OTCQB, providing investors with increased access to data, transparency and liquidity.

Green Growth Brands Inc. (OTCQB: GGBXF), closed the day's trading session at $3.4761, off by 1.72%, on 71,813 volume with 188 trades. The average volume for the last 3 months is 207,815 and the stock's 52-week low/high is $1.8068/$5.205.

Recent News

chart

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

ChineseInvestors.com Inc. (OTCQB: CIIX) has added a high-end, full-spectrum brand of CBD oil to its CBD offerings through subsidiary ChineseHempOil.com Inc. The new product line is available at www.365CWC.com. CIIX said in a news release that the new, branded oil should have a positive impact on its sales and profit margin (http://nnw.fm/CQq56). NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://nnw.fm/CIIX.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed the day's trading session at $0.50, up 0.99%, on 50,250 volume with 35 trades. The average volume for the last 3 months is 79,948 and the stock's 52-week low/high is $0.365/$1.25.

Recent News

chart

Sharing Services Global Corporation (SHRV)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRV).

Diversified holding company Sharing Services Global Corporation (OTCQB: SHRV) on Monday announced that Robert Oblon, founder of the company’s wholly owned subsidiary, Elepreneur LLC, is featured in the Spring 2019 issue of Networking Times. To view the full press release, visit: http://nnw.fm/yIN7g.

Sharing Services Global Corporation (SHRV), headquartered in Plano, Texas, is a diversified holdings company focused on reshaping how entrepreneurs succeed today. Sharing Services Inc. owns, operates or controls an interest in a variety of companies specializing in the direct selling industry that either sell products to the consumer directly through independent representatives or offer services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits. SHRV has created the “Blue Ocean Strategy,” which melds three keys together to implement the company’s vision. These keys include elevating home-based entrepreneurs, known as “Elepreneurs,” utilizing the direct selling channel to generate 100 percent organic growth.

Sharing Services Inc. subsidiaries include:

  • A growing international network of home-based entrepreneurs, called “Elepreneurs”
  • Growing selection of health and wellness products dedicated to elevating the well-being of all people
  • Insurance from auto, home and life to health benefit discounts and health insurance that help families elevate their options
  • Wholesale travel and payment programs with travel concierges that empower more families to go on vacation
  • Live seminars and training events – from Vacationars™ to EduTainment – that elevate the skills and knowledge of entrepreneurs around the world
  • Unique compensation and reward programs crafted to help entrepreneurs elevate their health, wealth and happiness

Sharing Services recently expanded its corporate footprint by moving to a 10,000 square foot facility in Plano, Texas, that offers room to expand as the company grows and its subsidiaries flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

“The opportunity to expand to the rest of this new building over the course of the next six to 12 months ensures we won’t have to move again anytime soon,” Sharing Services Inc. Chairman Robert Oblon said. “We are on track for very significant growth here in the U.S., as well as upcoming international expansion, so this move is in preparation for what’s in front of us.”

The company recently signed a joint venture agreement with Health Wealth & Happiness Limited (“HWH”) to expand its “Elepreneurs” brand and market its products throughout Asia. The newly formed company will be named “Elepreneurs Asia Limited” and will have marketing and sales rights to China, Hong Kong, Macau, South Korea, Japan, Taiwan, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam and Papua, New Guinea. A soft launch of the Elepreneur program is scheduled sometime later in 2018 with HWH CEP Fai Chan and his team leading the effort. Formed in Hong Kong, Health Wealth & Happiness Limited is dedicated to working with visionary partners like Sharing Services Inc. to deliver the best products and services to improve the well-being of consumers.

Nearly 1,000 people attended Sharing Services Global Corporation ’s first “Elepreneur Happiness Convention,” held March 2-3, 2018, in Dallas, Texas. Attendees arrived from several countries including the U.S., Canada, Mexico, Singapore and Hong Kong. Keynote speakers included several internationally known motivational leaders –  Shawn Achor, Sandra Yancey, John Fleming and Les Brown – who provided exceptional material and inspirational discussion points.

“The enthusiasm of our attendees and the early success that we are experiencing is incredible considering our growth has been 100 percent organic, with almost no marketing from the company,” Oblon said. “I’m speechless by the dedication of our Elepreneur leaders and their entire teams, as they share our incredible line of products that have helped so many people.”

Sharing Services and its management team plan to travel the U.S. to hold several mini conferences to expand on the messages presented at its Happiness Convention that focus on helping people become “healthier, happier and wealthier.” Details of the company’s aggressive global expansion initiatives are soon to be announced, Oblon said.

The law firm of Gardere Wynne Sewell LLP has been retained as outside corporate counsel for all general business matters. The Dallas-based law firm will represent Sharing Services Global Corporation , and its subsidiaries as the company utilizes the direct selling channel for a significant component of its overall growth strategy.

John “JT” Thatchwas appointed president and chief executive officer of Sharing Services Global Corporation , at a March 1, 2018, annual shareholder meeting. Thatch has successfully started, owned and operated several sized businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist Sharing Services Inc. as the company aims to expand and increase revenues.

Sharing Services Global Corporation (SHRV), closed the day's trading session at $0.22, off by 4.35%, on 1,176 volume with 1 trades. The average volume for the last 3 months is 45,877 and the stock's 52-week low/high is $0.17/$0.45.

Recent News

chart

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF)

The QualityStocks Daily Newsletter would like to spotlight FinCanna Capital Corp. (FNNZF).

Royalty company for the U.S. licensed medical cannabis industry FinCanna Capital (CSE: CALI) (OTCQB: FNNZF) today announced its election of Morris L. Reid to the position of chairman of the board. To view the full press release, visit: http://nnw.fm/wLdf6.

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) is a royalty company aiming to be the capital partner of choice for high-growth, best-in-class businesses operating in the licensed U.S. medical cannabis industry. Primarily focused on the burgeoning California cannabis market, FinCanna leverages extensive investment expertise and industry experience to benefit its shareholders and portfolio companies.

Medical Cannabis Market

According to Ameri Research, the global market for licensed medical cannabis is growing at a compound annual growth rate (CAGR) of more than 21%, on track to exceed $63.5 billion by 2024. Within this market, FinCanna has identified considerable opportunity in California, the fifth largest economy in the world and the largest medical cannabis market in North America. Arcview Group forecasts California’s legal cannabis industry will grow at 21.1% CAGR to $6.5 billion in 2020, generating more than $1 billion in tax revenue.

Royalty Model & Portfolio

FinCanna’s “whole capital” solution for businesses in the licensed medical cannabis sector includes the provision of capital investment for a percentage of their future revenues. The FinCanna Capital Solution utilizes a royalty arrangement to deliver capital, in order to facilitate the growth or other specific objectives of its investees, and ensure the business opportunity is optimized. This model provides an alternative or complement to debt and equity financing, allowing investees to maintain financial flexibility and control of their business rather than entering into arrangements that may include restrictive debt structures or giving up an ownership stake.

FinCanna’s portfolio includes Cultivation Technologies, Inc. (“CTI”), a team of experts from Fortune 150 agriculture, medical cannabis, law, engineering and technology companies. FinCanna is providing funding to CTI for its planned, fully entitled, large-scale indoor medical cannabis facility to be developed in Coachella, California.

CTI has established an interim medical cannabis extraction facility (the “Interim Facility”) that will produce licensed medical cannabis products until the Coachella Project is complete. CTI is currently expanding its product line, Coachella Premium, to include vaporizer cartridges. Initial market feedback gathered during the product development phase indicates that Coachella Premium’s vaporizer cartridges offer a unique proposition within the vaporizer market, one of the fastest growing verticals in the cannabis market.

The Interim Facility can process up to 6,000 pounds of biomass per month, the equivalent of approximately 3.7 million grams of raw oil per year, with room for expansion. It is expected that the completed Coachella Project will be able to process 30,000 to 50,000 pounds of biomass per month, or the equivalent of 18 million grams to 30 million grams of raw oil per year.

Additionally FinCanna has entered into a royalty agreement with Green Compliance, a provider of point-of-sale software solution (“ezGreen”) for licensed medical cannabis dispensaries and cultivators. Green Compliance helps its customers comply with both the Health Insurance Portability and Accountability Act (“HIPAA”) and State Laws by ensuring patients’ confidential data is being handled properly, helping to protect from possible security breaches and financial and criminal liability resulting from potential violations.

FinCanna has also signed binding term sheet with Oakland, California-based Gram Co Holdings, subject to due diligence by FinCanna. Gram Co is a cannabinoid research and refinement facility focused providing B2B and B2C products and services to licensed medical dispensaries, infused product manufacturers, and numerous others in the cannabis supply chain. The company is also retrofitting a large, state-of-the-art medical cannabis extraction laboratory, which is expected to be operating in 2018.

The foregoing contains forward-looking statements regarding Cultivation Technologies Inc. (“CTI”) which are subject to risks, uncertainties and contingencies which include, but are not limited to the statements relating the future construction and completion of the CTI medical cannabis facility in Coachella, California, and the projected biomass processing and raw oil production at the facility. Such forward looking statements are based on assumptions regarding the construction, completion and operations of CTI’s proposed facility, including that CTI will obtain the financing required to build and equip its proposed facility, that CTI will obtain the additional financing required operate the facility, that construction facility is completed on time and budget, that CTI obtains state licenses to operate on a permanent basis, and that the equipment used in the cultivation of medical cannabis performs at scale in a similar way it performs at CTI’s pilot tests.

FinCanna Capital Corp. (FNNZF), closed the day's trading session at $0.11, off by 9.91%, on 7,500 volume with 4 trades. The average volume for the last 3 months is 38,201 and the stock's 52-week low/high is $0.0577/$0.554.

Recent News

chart

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Marijuana Company of America, Inc. (OTC: MCOA) was highlighted today in a publication from Financialnewsmedia.com, describing how, while article after article describes the “newest” CBD infused product to hit the market, recently a report finally addressed the status of consumer behavior and consumption habits. Also today, NetworkNewsWire released a report on the company detailing how MCOA supports an array of portfolio businesses that participate in the cannabis industry. Primarily an industrial hemp business, MCOA’s hempSMART company is focused on producing premier-quality botanical supplements derived from organically grown industrial hemp and synergistic botanicals (http://nnw.fm/7BBpe). MCOA is headquartered in Escondido, California.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.014, off by 8.50%, on 13,869,829 volume with 439 trades. The average volume for the last 3 months is 12,419,983 and the stock's 52-week low/high is $0.01025/$0.0499.

Recent News

chart

TransCanna Holdings Inc. (CSE: TCAN)

The QualityStocks Daily Newsletter would like to spotlight TransCanna Holdings Inc. (CSE: TCAN).

TransCanna Holdings Inc. (CSE: TCAN) through its subsidiaries specializes in assisting clients who are cannabis farmers and manufacturers get recognized by end consumers who in turn purchase their products. TransCanna offers or will be offering services to support almost every aspect of the cannabis-related eco-system; from branding and design, to transportation and distribution, to marketing and sales.

California’s legalized adult-use recreational marijuana market opened for business January 1, 2018. The state’s Bureau of Cannabis Control is responsible for regulating all commercial activities in the state including cultivation, distribution and transportation. Moving cannabis products in the California marketplace is extremely challenging due to municipal and state laws and regulations, which can differ among cities and counties. Since cannabis remains illegal under federal law, Department of Transportation regulated companies are barred from participating in the market, which means companies looking to excel in the sector must hold a state-issued distributor license from the Bureau of Cannabis Control.

TransCanna has already entered into an Intellectual Property Rights and Royalty Agreement for the Track & Trace software platform required by the state of California. TCM Distribution, the operating company managed by TransCanna, has received a transportation and distribution permit from the city of Adelanto and a temporary transportation and distribution permit from the state of California. TransCanna has also executed a land lease to build a 10,000-square-foot transportation and distribution facility in Adelanto.

TransCanna is strategically creating a distribution network throughout California that places its facilities no further than a three-hour drive from most any client. The company is in the process of leasing or purchasing properly licensed and permitted warehouses strategically located throughout California along with new secure trucks, sprinter vans and/or armored vehicles.

TransCanna plans to create its own portfolio of branded products for the cannabis and hemp sectors. The company’s management team intends to translate the skills, knowledge and experience gained from a combined 60 years of branding and marketing experience in the music, professional sports and alcohol industries into TransCanna and the cannabis industry.

As part of the “TransCanna Way,” the company intends to manage most aspects of the supply chain from upper end procurement, branding, transportation and distribution, to marketing and sales.

Leading TransCanna as its CEO and chairman is James Pakulis, who has three decades of experience working with public and private entrepreneurial companies in a variety of emerging and high-growth sectors. He is formerly the president and a director of Lifestyle Delivery Systems Inc. (CSE: LDS) (OTCQB: LDSYF), a vertically integrated cannabis-related entity operating in California. Pakulis was chairman and CEO of General Cannabis Inc. which from 2010 to 2012 owned WeedMaps. Pakulis oversaw the company’s growth from zero to over $16 million in annual revenue in less than 24 months.

The company’s strategic advisors include individuals with extensive experience in branding, marketing, sales, distribution, production and supply chain management.

For additional information, call: (604) 609-6199

TransCanna Holdings Inc. (CSE: TCAN), closed the day's trading session at $5.49, up 19.87%, on 703,469 volume with 503 trades. The stock's 52-week low/high is $0.769/$5.489.

Recent News

chart

Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE)

The QualityStocks Daily Newsletter would like to spotlight Pacific Rim Cobalt Corp. (OTCQB: PCRCF).

Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) is a Canada-based exploration company focused on the acquisition and development of production-grade cobalt deposits, a key raw material input for the growing lithium-ion battery industry.

Pacific Rim Cobalt and its Cyclops Nickel-Cobalt Project, located in the Depapre District, Jayapura Regency, Papua Province, Republic of Indonesia, is uniquely positioned in a region with potentially the largest source of cobalt outside of Africa. Strategically located near China, the world’s largest cobalt buyer, the Cyclops Project is a laterite (iron-hosted) mineral prospect, rich in cobalt and nickel. Cobalt consumption in China is on-track to use over 8,000 tonnes of cobalt annually by 2021 for electric vehicle production alone and is projected to remain the world’s largest cobalt consumer for many years to come.

Global demand for renewable power is fueling a massive shift from traditional energy supply chain economics to cobalt-reliant lithium-ion batteries, the world’s most widely used power source for portable applications such as electric vehicles and other high-tech applications.

Pacific Rim Cobalt management has concluded that strategic access to major markets offers the most important factor to servicing the rising demand for cobalt. The company’s acquisition of its initial asset in Indonesia offers near surface, strong nickel-cobalt mineralization in an area with excellent infrastructure including a nearby workforce, supplies, sealed roads, ocean access, nearby port facility and gentle topography. The project area, nestled on the north coast of Papua, Indonesia, establishes Pacific Rim Cobalt well within the economically attractive ocean-going transportation range to Asia and its lucrative, growing industrial markets.

Exploration efforts are currently focused on establishing a maiden compliant resource for the Cyclops project, both in historically identified and drill-tested prospects as well as previously unexplored areas of the claims. During the first nine months of 2018, the company focused on assembling the necessary agreements to access northern areas of the project hosting historically identified mineralized zones. Mapping, sampling and a mini-bulk sample within the mineralized zones has been completed, along with a small-scale program in the previously unexplored far southern area of the project. With surface access to priority targets now established, Pacific Rim Cobalt will initiate drilling and extract additional mini-bulk samples for further metallurgical testing.

“We are excited and optimistic about the unique possibility of developing this project into an asset that will add shareholder value and position the company to play a future role in the battery metals supply chain,” Pacific Rim Cobalt CEO Ranjeet Sundher recently stated (http://nnw.fm/u1HNs). “We expect the near-surface nature of cobalt/nickel mineralization at the Cyclops project will lend itself well to low-cost, logistically straightforward drilling. We thus anticipate the opportunity to undertake a resource calculation study, as well as ongoing metallurgy and process option testing, will present itself in the near future. It’s going to be a busy year ahead, and we look forward to getting the drills turning and building value.”

Pacific Rim Cobalt’s world-class management team includes Sundher, who has over 20 years of capital markets experience. Sundher is also president of Canrim Ventures Ltd., a Singaporean advisory firm specializing in early stage project finance and structure. He previously founded Indogold Exploration, a Jakarta-based mining service firm, and has raised over $40 million for companies in which he was a founder/partner.

Chief Financial Officer Steve Vanry has 25 years of professional experience in senior management positions with public and private natural resources companies, providing expertise in capital markets corporate finance, mergers and acquisitions, regulatory compliance, accounting and financial reporting.

Andre Talaska serves as country manager and technical supervisor. He has over 30 years of experience in the mining and exploration industry and has held senior positions with several companies in Australia and southeast Asia. Shakir Juffry, business development/engineering, is a chemical engineer and extractive metallurgist by background training who has over 20 years of experience in the Indonesian mining and minerals exploration field. Toto Suarto Sajali, operation and development manager, is a mining engineer with over 15 years of experience in Indonesian project assessment, development and operations.

Pacific Rim Cobalt Corp. (OTCQB: PCRCF), closed the day's trading session at $0.22, up 2.90%, on 4,192 volume with 7 trades. The average volume for the last 3 months is 37,365 and the stock's 52-week low/high is $0.0701/$0.4375.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.